Lactobacillus paracasei Strain ST11 Has No Effect on Rotavirus but Ameliorates the Outcome of Nonrotavirus Diarrhea in Children From Bangladesh

• DOI: 10.1542/peds.2004-2334
• Publication Date: 2005-07-02T00:59:51Z
• Authors: Shafiqul A. Sarker; Shamima Sultana; George J. Fuchs; Nur H. Alam; Tasnim Azim; Harald Brüssow; Lennart Hammarström
• Keywords: Lactobacillus paracasei

Previous studies have shown that selected strains of lactobacilli are administered orally result in a modest reduction diarrhea duration. However, duration alone is not considered optimal for therapeutic evaluation any agent diarrhea.To examine the effect new probiotic, Lactobacillus paracasei strain ST11 (ST11), acute childhood by using criteria recommended World Health Organization.In randomized, double-blind, placebo-controlled clinical trial, 230 male infants and young children, 4 to 24 months age, presenting with <2 days' were admitted metabolic research ward International Centre Diarrheal Disease Research, Bangladesh, fed 10(10) colony-forming units lyophilized or placebo daily 5 days. Stool output frequency, oral rehydration solution intake, excretion rotavirus monitored daily.No treatment on severe was observed. probiotic did significantly reduce cumulative stool (225 +/- 218 vs 381 240 mL/kg), frequency (27.9 17 42.5 26), intake (180 207 331 236 mL/kg) children less-severe nonrotavirus compared those receiving treatment. A higher proportion had their resolve within 6 days therapy (ST11 versus placebo: 76% 49%).ST11 has clinically significant benefit management nonrotavirus-induced diarrhea, but it ineffective diarrhea.